Mark A. Tepper PhD

Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry. He has led drug discovery & drug development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS Diseases, Inflammation, and Pain. In addition, he has founded multiple companies based on novel technologies in the area of RNA interference, structure-based drug design, small molecule, and protein therapeutics, biosensors, microfluidics, and biomaterials. Following a 15-year career in large Pharma-R&D, Dr. Tepper became a serial entrepreneur where he founded multiple biotech companies based on technology spun out from academic institutions. His role in these companies included technology sourcing, due diligence, company formation, term sheet negotiations, capitalization, commercialization, business planning, operations, IP licensing, and executive management recruitment. At each of these companies, he served as part of the executive management team, helping to execute the business & development plan. In the last 17 years, Dr. Tepper has raised over $200M in capital for his ventures. He has taken two of his companies public and sold another company in a trade sale. His most recent venture is EuMentis Therapeutics focused on developing novel drugs for the treatment of neurodegenerative and neurodevelopmental disorders. Prior to that, he was President and Chief Scientific Officer of Corbus Pharmaceuticals (CRBP) which is developing novel breakthrough medicines to treat

serious life-threatening inflammatory and fibrotic diseases. It's lead drug candidate, Lenabasum is currently in phase 3 clinical trials with top-lien results expected in the summer of 2020. Corbus IPO’ed in 2014, and currently has a market cap of ~$400M His other companies have included; Primatope Therapeutics (acquired by Kiniksa in Feb 2019), developing novel best-in-class humanized CD40 monoclonal antibodies to treat autoimmune diseases and organ transplant rejection; NKT Therapeutics, developing medicines based on Natural Killer T Cells to treat sickle cell crisis and asthma; RXi Pharmaceuticals (NASDAQ: RXii) developing RNAi therapeutics to treat wound healing and scarring; and Arradial, which developed a microfluidics-based screening tool for identifying new drugs from human genome targets.

Dr. Tepper earned a Ph.D. in Biochemistry & Biophysics from Columbia University, College of Physicians and Surgeons, New York, and a B. An in Chemistry with Highest Honors from Clark University, Worcester, Mass. He did his postdoctoral fellowship at the University of Massachusetts Medical School, Worcester in the laboratory of Michael P. Czech. He has over 50 scientific publications and is the co-inventor of multiple drug-related patents. Dr. Tepper’s hobbies include SCUBA diving, fishing, boating, marine aquaria, beer making, and gardening.